Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
10/20Evotec short pitch at Robin Hood conference; shares fall 4%
1
10/19Forge Therapeutics, Evotec launch platform to discover metalloenzyme inhibito.. 
10/19Forge Therapeutics, Evotec launch platform to discover metalloenzyme inhibito..
1
10/12Evotec AG $EVTCY Upgraded at Zacks Investment Research  
10/12Evotec AG $EVTCY Rating Lowered to Hold at Zacks Investment Research  
10/11Evotec AG downgraded by Zacks Investment Research to hold.  
10/10Evotec Achieves First Milestone in Neurodegeneration Alliance with Celgene  
10/10BRIEF-Evotec achieves first milestone in neurodegeneration alliance with Celg.. 
10/10Evotec Achieves First Milestone in Neurodegeneration Alliance with Celgene: H.. 
10/10Evotec Achieves First Milestone in Neurodegeneration Alliance with Celgene  
10/10BRIEF-Evotec receives $5 million milestone in Celgene alliance  
10/10EVOTEC ACHIEVES FIRST MILESTONE IN NEURODEGENERATION ALLIANCE WITH CELGENE  
10/10Evotec AG upgraded by Zacks Investment Research to buy. $56.00 PT.  
09/28Evotec invests in Exscientia to advance AI-driven drug discovery  
09/28Evotec Invests in Exscientia to Advance AI-Driven Drug Discovery  
09/28Evotec Invests in Exscientia to Advance AI-Driven Drug Discovery  
09/28Evotec Invests in Exscientia to Advance AI-Driven Drug Discovery  
09/28Frontier IP : Exscientia announces investment from Evotec  
09/23Evotec AG upgraded by Zacks Investment Research to buy. $50.00 PT.  
09/22Evotec AG downgraded by Zacks Investment Research to hold.  
09/19Evotec AG given €16.00 PT by Berenberg Bank. neutral rating.  
09/18Evotec AG: </td>  
09/18Evotec AG  
09/18Evotec AG  
09/18Evotec AG: </td>  
09/14MARS INNOVATION AND EVOTEC AG ESTABLISH ACADEMIC BRIDGE “LAB150” IN TORONTO  
09/14MARS INNOVATION AND EVOTEC AG ESTABLISH ACADEMIC BRIDGE “LAB150” IN TORONTO  
09/14Evotec : und MaRS Innovation bilden Academic Bridge "LAB150" in Toronto  
09/14Evotec and MaRS Innovation Establish Academic Bridge 'LAB150' in Toronto  
09/14Evotec and MaRS Innovation Establish Academic Bridge 'LAB150' in Toronto
1
09/14Evotec and MaRS Innovation Establish Academic Bridge 'LAB150' in Toronto  
09/14EVOTEC UND MARS INNOVATION BILDEN ACADEMIC BRIDGE 'LAB150' IN TORONTO  
09/14EVOTEC UND MARS INNOVATION BILDEN ACADEMIC BRIDGE 'LAB150' IN TORONTO  
09/14Evotec and MaRS Innovation Establish Academic Bridge 'LAB150' in Toronto  
09/14EVOTEC AND MARS INNOVATION ESTABLISH ACADEMIC BRIDGE 'LAB150' IN TORONTO  
09/14EVOTEC UND MARS INNOVATION BILDEN ACADEMIC BRIDGE 'LAB150' IN TORONTO  
09/11European Investment Bank grants &euro;75m funding for Evotec -  
09/10EU investment plan finances innovative medical research with 75 million-euro .. 
09/08Evotec AG  
09/08Evotec AG: </td>  
09/08European Investment Bank Supports Evotec&amp;#39;s Innovate Strategy with.. 
09/08European Investment Bank Supports Evotec's Innovate Strategy with EUR 75 M Lo.. 
09/08European Investment Bank Supports Evotec's Innovate Strategy with EUR 75 M Lo.. 
09/08European Investment Bank Supports Evotec's Innovate Strategy with EUR 75 M Lo.. 
09/08Evotec : European Investment Bank Supports Evotec's Innovate Strategy with EU.. 
09/08EUROPEAN INVESTMENT BANK SUPPORTS EVOTEC'S INNOVATE STRATEGY WITH EUR 75 M LO.. 
09/07ABIVAX and Evotec Enter Into Strategic Collaboration to Develop Novel Antivir.. 
09/07Analysts’ Recent Ratings Changes for Evotec AG $EVTCY  
09/07Evotec AG And Abivax Enter Into Strategic Collaboration To Develop Novel Anti.. 
09/07Evotec and ABIVAX Enter into Strategic Collaboration to Develop Novel Antivir.. 
More tweets
Qtime:70
Financials (€)
Sales 2017 232 M
EBIT 2017 40,9 M
Net income 2017 26,8 M
Debt 2017 10,9 M
Yield 2017 -
P/E ratio 2017 104,25
P/E ratio 2018 72,17
EV / Sales 2017 12,0x
EV / Sales 2018 8,87x
Capitalization 2 768 M
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 13,2 €
Spread / Average Target -30%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG152.15%3 261
INCYTE CORPORATION13.96%24 054
QUINTILES IMS HOLDINGS INC35.48%22 162
LONZA GROUP59.15%19 392
CELLTRION, INC.--.--%19 297
ALNYLAM PHARMACEUTICALS, INC.206.36%10 522